ERBB2 and breast carcinoma: On this foundation, early-phase clinical trials can be designed in high-risk cardio-oncology cohorts, for example breast cancer patients receiving anthracyclines or HER2-targeted therapy, with endpoints including cardiac MRI for functional remodeling, circulating biomarkers of ferroptosis and inflammation, and oncologic response rates.